Samantha Jaglowski, MD, MPH, on Next Steps Regarding Tisagenlecleucel for Patients with DLBCL

News
Article

The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.

Samantha Jaglowski, MD, MPH, associate professor at The Ohio State University Comprehensive Cancer Center, discussed next steps regarding her analysis of the CAR T-cell therapy tisagenlecleucel (Kymriah) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) using the Center for International Blood and Marrow Transplant Research (CIBMTR) database at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, in Orlando, Florida.

Transcription:
Really the next step is, this is really very germinal, this is the first readout of the tisagen data submitted to the CIBMTR, so the next steps are really going to be to accrue more patients. There’s a goal of collecting 2,500 tisagen patients and currently there are a bit over 100 that we’re reporting on, so the goal is for this to be a really large suppository of data and we’re not there yet. We will be there, but you know it’ll be important to continue to follow this with time.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Related Content
Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Sonrotoclax Elicits Responses in Relapsed/Refractory Mantle Cell Lymphoma

Kyle Doherty
December 8th 2025
Article

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The FDA approved pirtobrutinib as a treatment for patients with CLL/SLL who received prior BTK inhibition based on the phase 3 BRUIN-CLL-321 trial results.

Pirtobrutinib Exhibits Favorable Efficacy in R/R Follicular Lymphoma

Roman Fabbricatore
December 8th 2025
Article

The FDA approved pirtobrutinib as a treatment for patients with CLL/SLL who received prior BTK inhibition based on the phase 3 BRUIN-CLL-321 trial results.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

Caroline Seymour
December 8th 2025
Article

“Pirtobrutinib continues to show favorable efficacy and promising overall survival [OS],” said William G. Wierda, MD, PhD.

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL

Kristie L. Kahl
December 7th 2025
Article

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.